Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
189,947,836
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
95,071,148
-
Shares change
-
+2,395,403
-
Total reported value, excl. options
-
$474,405,111
-
Value change
-
+$9,854,270
-
Put/Call ratio
-
173%
-
Number of buys
-
80
-
Number of sells
-
-66
-
Price
-
$4.99
Significant Holders of Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) as of Q2 2024
169 filings reported holding WVE - Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share as of Q2 2024.
Wave Life Sciences Ltd. - Common Stock, $0.00001 par value per share (WVE) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95,071,148 shares
of 189,947,836 outstanding shares and own 50% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (18,202,009 shares), MAVERICK CAPITAL LTD (7,669,361 shares), BlackRock Inc. (6,738,735 shares), M28 Capital Management LP (6,164,548 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (5,357,719 shares), 683 Capital Management, LLC (5,325,000 shares), Artal Group S.A. (4,566,251 shares), Bellevue Group AG (4,094,458 shares), Kynam Capital Management, LP (3,975,521 shares), and PRIMECAP MANAGEMENT CO/CA/ (2,664,216 shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.